Table 5: Recent randomised controlled trials of weight loss therapies with 12-month followup.

DrugNo. subjectsOutcomesSerious adverse eventsReference
Absolute weight loss (kg) (95% CI)≥5% weight loss≥10% weight lossChange in WC (cm)

LorcaserinPlacebo-716 20.3%7.7% Headache 2% P, 0.8% L [120]
L-883 47.5 Dizziness 0.8% P, 0.1% L

TaranabantPlacebo-4172.6 (1.8, 3.3)27.2%8.4%−3.1 (2.3, 3.9)Nausea 6.5% P, 16.7% TB 2 mg, 21.4% TB 4 mg, [31]
TB 2 mg-4156.6 (5.9, 7.4), 56.5%, 27.9%, −7.0 (6.1, 8.1), Vomiting 3.4% P, 8.4 TB 4 mg,
TB 4 mg-4148.1 (7.4, 8.9), 64.2%, 35.8%,  −7.5 (6.7, 8.3), Diarrhoea 7.2% P, 12.3 TB 2 mg, , 13.7% TB 4 mg,
Anxiety 3.4 P, 9.9 TB 4 mg,

TaranabantPlacebo-196+1.7 (0.8, 2.7)62.2%NR−0.7 (−0.3, 1.8)Irritability TB 1 mg and 2 mg, [116]
TB 0.5 mg-1960.1 (−1.0, 0.8), 71.8%NR−1.5 (−2.6, −0.5)
TB 1 mg-1960.6 (−1.5, 0.4), 78%, NR−2.3 (−3.4, −1.3)
TB 2 mg-1961.2 (−2.1, −0.3), 83.3%, NR−2.4 (−3.4, −1.3)

TaranabantPlacebo-1371.4 (−0.5, −2.4)24.3%7.3%−3.0 (−1.9, −4.1)Psychiatric-17.7% P, 28.8% TB1mg, 29%TB 2 mg, [118]
TB 0.5 mg-1415.0 (−4.0, −5.9), 44.2, 21.3, −5.6 (−4.5, −6.6),
TB 1 mg-1385.2 (−4.2, −6.2), 45.3, 18.2, −5.7 (−4.6, −6.7),
TB 2 mg-2776.4 (−5.7, −7.2), 53, 28, −6.9 (−6.1, −7.7),

Bupropion/naltrexone*Placebo-202 .9%60.4%30.2%−6.8 (5.3, 8.3)Nausea 10.5% P, 34.1% BN [121]
BN 360/32–591 , 80.4%, 55.2%, −10.0 (9.0, 10.9), Dizziness 4.5% P, 14.6% BN,
Bupropion/naltrexoneB-60 33%12%NANA[22]
BN 16 mg-64 50%22%
BN 32 mg-63 , 51%25%
BN 48 mg-61 39%20%

PramlintidePlacebo-63Pramlintide-61
3%
28%
11% 
36%
NRNausea 0% P, 30% Pramlintide[85]

TopiramatePlacebo-55
T−54

,
19% 
50%,
2% 
20%,

,
Paraesthesia −0% P, 28% TPsychiatric −11% P, 33% T[122]

Topiramate/phentermineP-4981.617%NANANA [123]
TP 3.75/23 mg-2345.1, 45%,
TP15/92 mg-49811, 67%,

Topiramate/phentermineP-9791.8 21% NANANA [123]
TP 7.5/46 mg-4888.4, 62%,
TP15/92 mg-98110.4, 70%,

Absolute weight loss: weight loss from baseline; NS: not significant, NA: not available; L: lorcaserin; NB: naltrexone/bupropion, TB: taranabant; T: topiramate controlled release; TP: topiramate/phentermine; mean  ±  standard error; *both groups also received intensive behavior modification.